Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

Amulya A.Nageswara Rao; Grace M. Arteaga; Ann M. Reed; James M. Gloor; Vilmarie Rodriguez

doi:10.1002/pbc.21878

Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

Amulya A.Nageswara Rao, Grace M. Arteaga, Ann M. Reed, James M. Gloor, Vilmarie Rodriguez

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

Original language	English (US)
Pages (from-to)	536-538
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	52
Issue number	4
DOIs	https://doi.org/10.1002/pbc.21878
State	Published - Apr 2009

Keywords

Catastrophic antiphospholipid syndrome
Lupus anticoagulant;rituximab; thrombosis

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.21878

Cite this

@article{f6f12c09cf7f486f9fbd4a2ab09f7af9,

title = "Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome",

abstract = "Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.",

keywords = "Catastrophic antiphospholipid syndrome, Lupus anticoagulant;rituximab; thrombosis",

author = "Rao, {Amulya A.Nageswara} and Arteaga, {Grace M.} and Reed, {Ann M.} and Gloor, {James M.} and Vilmarie Rodriguez",

year = "2009",

month = apr,

doi = "10.1002/pbc.21878",

language = "English (US)",

volume = "52",

pages = "536--538",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

AU - Rao, Amulya A.Nageswara

AU - Arteaga, Grace M.

AU - Reed, Ann M.

AU - Gloor, James M.

AU - Rodriguez, Vilmarie

PY - 2009/4

Y1 - 2009/4

N2 - Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

AB - Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

KW - Catastrophic antiphospholipid syndrome

KW - Lupus anticoagulant;rituximab; thrombosis

UR - http://www.scopus.com/inward/record.url?scp=62449319386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449319386&partnerID=8YFLogxK

U2 - 10.1002/pbc.21878

DO - 10.1002/pbc.21878

M3 - Article

C2 - 19061212

AN - SCOPUS:62449319386

SN - 1545-5009

VL - 52

SP - 536

EP - 538

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this